Aptose regains Nasdaq minimum bid price compliance; equity rule still breached

Aptose Biosciences Inc.

Nasdaq confirmed closing bid price at or above $1.00 for 10 consecutive business days as of March 14, 2025.
Aptose remains non-compliant with Nasdaq's $2.5M shareholders' equity requirement.
Company operates under a Hearing Panel exception to regain equity compliance, but no assurance of success.
Aptose is a clinical-stage precision oncology firm developing tuspetinib-based triple therapy for newly diagnosed AML.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.